Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Mol – page 58

1 758 clinical trials in Mol, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mol at a glance
1 758
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 758 trials in Mol

Open in trial search

Lupus nephritis+2

Not yet recruiting

Phase 2 Open‑Label Trial Assessing Safety and Efficacy of Nebaprubart in Adults with IgA‑Mediated Renal Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:JJP BIOLOGICS Sp. z o.o.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colon cancer

Not yet recruiting

Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Solstice Oncology Inc.

Pulmonary hypertension

Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiac failure+5

Not yet recruiting

Safety and Early Effectiveness of Intramyocardial Cardiac Atrial Stem Cells Compared with Sodium Chloride in Patients with Advanced Ischemic Heart Failure

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CASCS
  • Sponsor:CASC8

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not yet recruiting

Clinical trial of subcutaneous infliximab in patients with perianal fistulizing Crohn’s disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:CHU De Liege

Bronchiectasis

Not yet recruiting

Efficacy and safety of galvokimig in adults with non‑cystic fibrosis bronchiectasis: a randomized, double‑blind, placebo‑controlled phase 2 trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Bronchitis+1

Not yet recruiting

Study of galvokimig versus placebo to assess safety and effectiveness in adults with moderate‑to‑severe chronic obstructive pulmonary disease with chronic bronchitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mol

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on cardiovascular conditions, specifically examining new therapeutic approaches for heart-related disorders.

  • Atrial Fibrillation Studies
  • Acute Coronary Syndrome Research
  • Stroke Prevention Initiatives

These studies evaluate novel treatments targeting cardioembolic events and investigating approaches to reduce recurrent cardiovascular events in patients with various heart conditions.

02 Cardiac Therapeutics

Research centered on developing and testing new cardiovascular medications for improving patient outcomes in heart-related conditions.

  • Heart Attack Prevention
  • Systemic Embolism Prevention
  • Cardiovascular Risk Management

The studies aim to evaluate therapeutic effectiveness in reducing major adverse cardiac events and improving long-term patient outcomes.

03 Preventive Cardiology

Clinical research focusing on preventive measures for cardiac complications and stroke in high-risk patients.

  • Post-Heart Attack Care
  • Stroke Risk Reduction
  • Cardiac Event Prevention

These trials examine innovative approaches to prevent recurring cardiovascular events and improve standard-of-care treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.